​
​

CytomX Therapeutics Ownership | Who Owns CytomX Therapeutics?

OverviewForecastRevenueFinancialsChartTranscripts

CytomX Therapeutics Ownership Summary

CytomX Therapeutics is owned by 61.79% institutional investors, 1.00% insiders, and 37.21% retail investors. Tang capital management is the largest institutional shareholder, holding 9.50% of CTMX shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 3.14% of its assets in CytomX Therapeutics shares.

CTMX Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockCytomX Therapeutics61.79%1.00%37.21%
SectorHealthcare Stocks 47.38%7.99%44.63%
IndustryBiotech Stocks 45.43%7.81%46.75%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Tang capital management7.79M9.50%$9.51M
Janus henderson group6.30M7.68%$7.72M
Bvf inc/il5.23M6.37%$6.38M
Vanguard group4.89M5.96%$5.97M
Adage capital partners gp3.00M3.66%$3.66M
Acadian asset management2.73M3.33%$3.32M
Millennium management1.85M2.25%$2.25M
Laurion capital management lp1.53M1.86%$1.86M
Jacobs levy equity management1.51M1.84%$1.84M
Schonfeld strategic advisors1.38M1.68%$1.68M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Tang capital management7.79M0.97%$9.51M
Congress park capital1.15M0.57%$1.41M
Bvf inc/il5.23M0.18%$6.38M
Adar1 capital management572.17K0.13%$698.05K
Formidable asset management258.00K0.05%$314.76K
Forefront analytics64.06K0.04%$78.16K
Laurion capital management lp1.53M0.02%$1.86M
Cornercap investment counsel80.59K0.02%$98.32K
Schonfeld strategic advisors1.38M0.01%$1.68M
Bridgeway capital management369.12K0.01%$450.33K

Top Buyers

HolderShares% AssetsChange
Janus henderson group6.30M0.00%6.30M
Tang capital management7.79M0.97%1.34M
Millennium management1.85M0.00%1.17M
Adage capital partners gp3.00M0.01%1.00M
Jacobs levy equity management1.51M0.01%977.78K

Top Sellers

HolderShares% AssetsChange
Orbimed advisors---3.54M
Sio capital management---1.60M
Bvf inc/il5.23M0.18%-1.37M
Rtw investments, lp---1.20M
Superstring capital management lp---1.15M

New Positions

HolderShares% AssetsChangeValue
Janus henderson group6.30M0.00%6.30M$7.72M
Sei investments382.72K0.00%382.72K$466.92K
Creative planning107.00K0.00%107.00K$130.54K
Stifel financial47.10K0.00%47.10K$57.46K
Invesco23.09K-23.09K$28.18K

Sold Out

HolderChange
Innealta capital-2.00
Old point trust & financial services n a-250.00
Wells fargo & company/mn-524.00
Macquarie group-1.13K
Whittier trust-2.20K

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 202477-15.38%50,687,25714.42%611.72%42-8.70%23-8.00%
Mar 31, 20249133.82%44,300,46236.07%603.69%4691.67%2525.00%
Dec 31, 2023687.94%32,557,3140.67%401.71%2471.43%20-20.00%
Sep 30, 202363-7.35%32,341,071-5.07%481.84%14-44.00%2531.58%
Jun 30, 202368-11.69%34,068,157-4.15%511.79%2525.00%19-47.22%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv2.46M3.14%-
Vanguard Institutional Extnd Mkt Idx Tr981.49K1.26%-
Vanguard Explorer Inv820.46K1.05%-
Vanguard Strategic Small-Cap Equity Inv555.12K0.71%-
Fidelity Extended Market Index457.69K0.59%8.09K
Acadian Global Small-Cap Equity CIT Cl A382.72K0.49%382.72K
Formidable ETF246.00K0.31%-
Vanguard VIF Small Co Gr235.81K0.30%-
Candriam Global Equities Oncology210.00K0.27%210.00K
Bridgeway Ultra-Small Company Market188.50K0.24%-

Recent Insider Transactions

DateNameRoleActivityValue
Aug 20, 2024Landau Jeffrey B Chief Business OfficerSell$5.14K
Aug 20, 2024BELVIN MARCIA SVP, Chief Scientific OfficerSell$5.14K
Aug 20, 2024ROWLAND LLOYD A General CounselSell$5.14K
Aug 20, 2024Ogden Christopher Chief Financial OfficerSell$2.44K
Aug 20, 2024McCarthy Sean A. CEOSell$17.08K

Insider Transactions Trends

DateBuySell
2024 Q3-5
2024 Q2--
2024 Q1-5
2023 Q4-5
2023 Q3-4

CTMX Ownership FAQ

Who Owns CytomX Therapeutics?

CytomX Therapeutics shareholders are primarily institutional investors at 61.79%, followed by 1.00% insiders and 37.21% retail investors. The average institutional ownership in CytomX Therapeutics's industry, Biotech Stocks , is 45.43%, which CytomX Therapeutics exceeds.

Who owns the most shares of CytomX Therapeutics?

CytomX Therapeutics’s largest shareholders are Tang capital management (7.79M shares, 9.50%), Janus henderson group (6.3M shares, 7.68%), and Bvf inc/il (5.23M shares, 6.37%). Together, they hold 23.56% of CytomX Therapeutics’s total shares outstanding.

Does Blackrock own CytomX Therapeutics?

BlackRock is not among the top 10 institutional shareholders of CytomX Therapeutics.

Who is CytomX Therapeutics’s biggest shareholder by percentage of total assets invested?

Tang capital management is CytomX Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.97% of its assets in 7.79M CytomX Therapeutics shares, valued at 9.51M$.

Who is the top mutual fund holder of CytomX Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of CytomX Therapeutics shares, with 3.14% of its total shares outstanding invested in 2.46M CytomX Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools